SlideShare une entreprise Scribd logo
1  sur  25
Medical & Scientific Affairs (M & SA) A critical piece in the puzzle of building organizational equity Dr Karthik Anantharaman Head of Medical Team Integrated Disease Management Pvt Ltd
Presentation outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Objective of M & SA function understood to be in line with the  Vision of the organization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Market Leadership Partner of choice Employer of choice Patient
Roles & Responsibilities of M & SA understood to be in-line with  Differentiated Strategic Intent of organization Customer Few Disease Management Many Product Therapeutic Areas Offering Doctor Patients IDM Scientific rigour for patented ‘first in class’ brands Establish both ‘Science’ & ‘Story’ of the brand Health Outcome Partner to physicians to improve patient outcomes Establish brand as a ‘SOLUTION’ & not a tablet Most Large Pharma  Companies in India “ Differentiated” Intent
M & SA responsibility: The fine balance Scientific & Research based communication – Non product related, Focus on Disease Management, Guideline Compliance (fair, balanced, non-promotional, build organizational equity thru scientific excellence)  Science based product related discussions / objection handling / query management
Vision & Mission Statements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Alignment to the organizational strategy  Complete alignment for the flawless execution and implementation of the strategy in accordance with the business needs.
M & SA : The New Industry Model ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
D.  Future H S A Working Model ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],M & SA  activities  shall have 2 components:  Activities common to all  members of  M & SA  +  Activities specific to  BU specific  M & SA
M & SA Responsibilities on lines of  Pharmaceutical Organizational Priorities (1) Direct Business Development Priorities (Conventional) (2) Incremental Business Development Priorities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Responsibilities of M & SA  Sales Marketing RTM KAM  M & SA Medical / MRL / Regulatory Corporate Business (1) Direct Business Development Priorities (Conventional)
Responsibilities of M & SA  Sales PV IDM  Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships CSR (2) Incremental Business Development Priorities PCP / Patient Support Programs
Completing the picture: All Responsibilities of M & SA  Sales Marketing RTM KAM  PV IDM  Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships  Corporate Business CSR CSA / Patient Support Counselors
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Defining individual responsibilities of M & SA
Role of Team M & SA in Business Strategy Strategy building team BUD + Marketing  + NBM Head – M & SA  Output = BU Strategy Strategy roll-out team Medical Advisor Marketing Manager M & SA Manager M & SA Implementation Pre-implementation (if any) (blue) & Post-implementation (green) M & SA  Inputs / feedback Into BU Strategy (Attachment 1)
M & SA  : Feedback & Performance Management Customers of M & SA  Internal customers (Sales & Marketing) External customers (Doctors) *RBM feedback on respective  M & SA(monthly)  (Attachment 4) **Training feedback (Attachment 5) M & SA Mgr Consolidated monthly feedback to individual M & SA  Individual Coaching & Counseling Supervisor Doctor feedback (consolidated monthly): **CME quality feedback (Attachment 6) **Medical Query quality feedback (Attachment 7) M & SA  Manager Monthly Field trip report  (Attachment 8) Assessment of Business Enabling Capabilities Assessment of Technical &  Management capabilities Assessment of Technical capabilities *Reported on last working day of the month **incorporated in monthly report
PPG/KRA Alignment of Team M & SA  Head M & SA  Regional  M & SA  Mgr Regional  M & SA  Mgr M & SA M & SA Regional  M & SA  Mgr M & SA Medical Director S & M Director  (consolidated for all BUs) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG)
Resource Planning - Methodology Variables Weightage CoP Network (Region-wise) (Focus segment for KOL Management) 50% Field Deployment 50% Number of medico-marketing activities based on BU strategy
 
Back-up Slides
Scope for future M & SA Job enrichment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

Highlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesHighlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesExL Pharma
 
Highlights From 7th Medical Science Liaison/MSL Conference
Highlights From 7th Medical Science Liaison/MSL ConferenceHighlights From 7th Medical Science Liaison/MSL Conference
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
 
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
 
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...Medical Science Liaison Society
 
Medical Science Liaison Webinarv 2009
Medical Science Liaison  Webinarv  2009Medical Science Liaison  Webinarv  2009
Medical Science Liaison Webinarv 2009Cameron Tew
 
New Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical IndustryNew Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical IndustryAnthony Russell
 
New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEFDuke Heart
 
Step-by-step Physician Marketing
Step-by-step Physician MarketingStep-by-step Physician Marketing
Step-by-step Physician MarketingEndeavor Management
 
Strategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesStrategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesAnjan Banerjee
 
5 healthcare technology transformation trends to watch out for in 2017
5 healthcare technology transformation trends to watch out for in 20175 healthcare technology transformation trends to watch out for in 2017
5 healthcare technology transformation trends to watch out for in 2017Rahul Gupta
 
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Manny Garcia MD
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketingFarhad Zargari
 
KOL Relationship Management in Pharma
KOL Relationship Management in PharmaKOL Relationship Management in Pharma
KOL Relationship Management in PharmaAnup Soans
 
Be a Smart Manager not just a good one!
Be a Smart Manager not just a good one!Be a Smart Manager not just a good one!
Be a Smart Manager not just a good one!Jean-Michel Peny
 
Academic Clinical Trial
Academic Clinical Trial Academic Clinical Trial
Academic Clinical Trial Airra Pagdato
 
Pharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report SummaryPharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report SummaryMarty Daniel with ThunderActive
 

Tendances (20)

Highlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesHighlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best Practices
 
Highlights From 7th Medical Science Liaison/MSL Conference
Highlights From 7th Medical Science Liaison/MSL ConferenceHighlights From 7th Medical Science Liaison/MSL Conference
Highlights From 7th Medical Science Liaison/MSL Conference
 
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)
 
Introduction to Medico-Marketing
Introduction to Medico-MarketingIntroduction to Medico-Marketing
Introduction to Medico-Marketing
 
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
 
Patient centric strategy
Patient centric strategyPatient centric strategy
Patient centric strategy
 
Medical Science Liaison Webinarv 2009
Medical Science Liaison  Webinarv  2009Medical Science Liaison  Webinarv  2009
Medical Science Liaison Webinarv 2009
 
New Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical IndustryNew Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical Industry
 
ISCHEMIA Trial
ISCHEMIA TrialISCHEMIA Trial
ISCHEMIA Trial
 
New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEF
 
Step-by-step Physician Marketing
Step-by-step Physician MarketingStep-by-step Physician Marketing
Step-by-step Physician Marketing
 
Strategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devicesStrategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devices
 
5 healthcare technology transformation trends to watch out for in 2017
5 healthcare technology transformation trends to watch out for in 20175 healthcare technology transformation trends to watch out for in 2017
5 healthcare technology transformation trends to watch out for in 2017
 
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
 
market research oncology
market research oncologymarket research oncology
market research oncology
 
KOL Relationship Management in Pharma
KOL Relationship Management in PharmaKOL Relationship Management in Pharma
KOL Relationship Management in Pharma
 
Be a Smart Manager not just a good one!
Be a Smart Manager not just a good one!Be a Smart Manager not just a good one!
Be a Smart Manager not just a good one!
 
Academic Clinical Trial
Academic Clinical Trial Academic Clinical Trial
Academic Clinical Trial
 
Pharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report SummaryPharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report Summary
 

Similaire à Medical & Scientific Affairs (M & SA)

MAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFMAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFElena Rizova
 
E J (Ted) Shaw CV
E J (Ted) Shaw CVE J (Ted) Shaw CV
E J (Ted) Shaw CVTed Shaw
 
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsMarketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsLegato Marketing & Communications
 
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008A.R.J. (Rob) Halkes
 
Lynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn Smith
 
Wendy W Starr Resume
Wendy W Starr ResumeWendy W Starr Resume
Wendy W Starr ResumeWendy Starr
 
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber HelalMahmoud Bahgat
 
Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007A.R.J. (Rob) Halkes
 
Radiometer 30 60 90
Radiometer 30 60 90Radiometer 30 60 90
Radiometer 30 60 90jfreshour
 
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Best Practices, LLC
 
The physician referral pathway
The physician referral pathwayThe physician referral pathway
The physician referral pathwayCary Wing
 
Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009lillianthiemann
 
2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedinSal Cofoni
 
Pharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgPharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgA.R.J. (Rob) Halkes
 
Senior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSenior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSimon Claridge
 

Similaire à Medical & Scientific Affairs (M & SA) (20)

Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
 
Entry into the pharmaceutical and medical industry
Entry into the pharmaceutical and medical industryEntry into the pharmaceutical and medical industry
Entry into the pharmaceutical and medical industry
 
MAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAFMAF Forum July 2013- Regional MAF
MAF Forum July 2013- Regional MAF
 
CV New
CV NewCV New
CV New
 
E J (Ted) Shaw CV
E J (Ted) Shaw CVE J (Ted) Shaw CV
E J (Ted) Shaw CV
 
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health ClinicsMarketing Techniques for Health System/Hospital-Based Retail Health Clinics
Marketing Techniques for Health System/Hospital-Based Retail Health Clinics
 
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
Value Innovation To Pharma - What Changes To Busisness, Zurich 2008
 
Lynn m. smith sales resume concise
Lynn m. smith sales resume conciseLynn m. smith sales resume concise
Lynn m. smith sales resume concise
 
Wendy W Starr Resume
Wendy W Starr ResumeWendy W Starr Resume
Wendy W Starr Resume
 
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
14th Cairo Marketing Club (FMCG Fast Moving Pharma)) by Dr.Saber Helal
 
Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007Towards Value Innovation In Pharma SFE Conference London 062007
Towards Value Innovation In Pharma SFE Conference London 062007
 
Radiometer 30 60 90
Radiometer 30 60 90Radiometer 30 60 90
Radiometer 30 60 90
 
A shock to the system
A shock to the systemA shock to the system
A shock to the system
 
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
 
The physician referral pathway
The physician referral pathwayThe physician referral pathway
The physician referral pathway
 
Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009Vivid Provider Mini Capabilities 2009
Vivid Provider Mini Capabilities 2009
 
A Day in the Life of a Medical Director
A Day in the Life of a Medical DirectorA Day in the Life of a Medical Director
A Day in the Life of a Medical Director
 
2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin2018 re con capabilitieslinkedin
2018 re con capabilitieslinkedin
 
Pharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.PetersburgPharma "beyond the pil" - master class in St.Petersburg
Pharma "beyond the pil" - master class in St.Petersburg
 
Senior Manager Global Medical Affairs
Senior Manager Global Medical AffairsSenior Manager Global Medical Affairs
Senior Manager Global Medical Affairs
 

Plus de Dr Karthik Anantharaman

Nov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsNov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsDr Karthik Anantharaman
 
Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr Karthik Anantharaman
 
Defibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDefibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDr Karthik Anantharaman
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117Dr Karthik Anantharaman
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015Dr Karthik Anantharaman
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Dr Karthik Anantharaman
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015Dr Karthik Anantharaman
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Dr Karthik Anantharaman
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117Dr Karthik Anantharaman
 
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechEHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechDr Karthik Anantharaman
 

Plus de Dr Karthik Anantharaman (20)

Nov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors DefibrillatorsNov 2016 Medical Buyer Patient Monitors Defibrillators
Nov 2016 Medical Buyer Patient Monitors Defibrillators
 
Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016Dr KA Marketing Transformation Summit 4th Aug 2016
Dr KA Marketing Transformation Summit 4th Aug 2016
 
Start Ups
Start UpsStart Ups
Start Ups
 
Defibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer FeatureDefibrillators Nov 2015 Medical Buyer Feature
Defibrillators Nov 2015 Medical Buyer Feature
 
Karthik_Singapore Med Dev Asia Nov 2015
Karthik_Singapore Med Dev Asia Nov 2015Karthik_Singapore Med Dev Asia Nov 2015
Karthik_Singapore Med Dev Asia Nov 2015
 
Karthik_Shanghai
Karthik_ShanghaiKarthik_Shanghai
Karthik_Shanghai
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117
 
eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014
 
ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015ECG Publication Medical Buyer March 2015
ECG Publication Medical Buyer March 2015
 
Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014Color Doppler Publication Medical Buyer June 2014
Color Doppler Publication Medical Buyer June 2014
 
eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015eHealth Connected Healthcare July 2015
eHealth Connected Healthcare July 2015
 
KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117KA Publication mHealth Feb 2015 JNPPR-2-117
KA Publication mHealth Feb 2015 JNPPR-2-117
 
Lifephone B2B
Lifephone B2BLifephone B2B
Lifephone B2B
 
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med TechEHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
EHealth Awards Dec 2014 PPT Dr KA BPL Med Tech
 
Comparison Of The Major Carbapenems
Comparison Of The Major CarbapenemsComparison Of The Major Carbapenems
Comparison Of The Major Carbapenems
 
Dr KA Apicon Master Slide Presentation
Dr KA Apicon Master Slide PresentationDr KA Apicon Master Slide Presentation
Dr KA Apicon Master Slide Presentation
 
Msd Trivandrum Dr Ka
Msd Trivandrum Dr KaMsd Trivandrum Dr Ka
Msd Trivandrum Dr Ka
 
Msd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr KaMsd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr Ka
 

Medical & Scientific Affairs (M & SA)

  • 1. Medical & Scientific Affairs (M & SA) A critical piece in the puzzle of building organizational equity Dr Karthik Anantharaman Head of Medical Team Integrated Disease Management Pvt Ltd
  • 2.
  • 3.
  • 4. Roles & Responsibilities of M & SA understood to be in-line with Differentiated Strategic Intent of organization Customer Few Disease Management Many Product Therapeutic Areas Offering Doctor Patients IDM Scientific rigour for patented ‘first in class’ brands Establish both ‘Science’ & ‘Story’ of the brand Health Outcome Partner to physicians to improve patient outcomes Establish brand as a ‘SOLUTION’ & not a tablet Most Large Pharma Companies in India “ Differentiated” Intent
  • 5. M & SA responsibility: The fine balance Scientific & Research based communication – Non product related, Focus on Disease Management, Guideline Compliance (fair, balanced, non-promotional, build organizational equity thru scientific excellence) Science based product related discussions / objection handling / query management
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Responsibilities of M & SA Sales Marketing RTM KAM M & SA Medical / MRL / Regulatory Corporate Business (1) Direct Business Development Priorities (Conventional)
  • 11. Responsibilities of M & SA Sales PV IDM Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships CSR (2) Incremental Business Development Priorities PCP / Patient Support Programs
  • 12. Completing the picture: All Responsibilities of M & SA Sales Marketing RTM KAM PV IDM Office of Compliance M & SA Medical / MRL / Regulatory External Partnerships Corporate Business CSR CSA / Patient Support Counselors
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19. Role of Team M & SA in Business Strategy Strategy building team BUD + Marketing + NBM Head – M & SA Output = BU Strategy Strategy roll-out team Medical Advisor Marketing Manager M & SA Manager M & SA Implementation Pre-implementation (if any) (blue) & Post-implementation (green) M & SA Inputs / feedback Into BU Strategy (Attachment 1)
  • 20. M & SA : Feedback & Performance Management Customers of M & SA Internal customers (Sales & Marketing) External customers (Doctors) *RBM feedback on respective M & SA(monthly) (Attachment 4) **Training feedback (Attachment 5) M & SA Mgr Consolidated monthly feedback to individual M & SA Individual Coaching & Counseling Supervisor Doctor feedback (consolidated monthly): **CME quality feedback (Attachment 6) **Medical Query quality feedback (Attachment 7) M & SA Manager Monthly Field trip report (Attachment 8) Assessment of Business Enabling Capabilities Assessment of Technical & Management capabilities Assessment of Technical capabilities *Reported on last working day of the month **incorporated in monthly report
  • 21. PPG/KRA Alignment of Team M & SA Head M & SA Regional M & SA Mgr Regional M & SA Mgr M & SA M & SA Regional M & SA Mgr M & SA Medical Director S & M Director (consolidated for all BUs) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG) BU specific (Aligned to BUD’s PPG)
  • 22. Resource Planning - Methodology Variables Weightage CoP Network (Region-wise) (Focus segment for KOL Management) 50% Field Deployment 50% Number of medico-marketing activities based on BU strategy
  • 23.  
  • 25.

Notes de l'éditeur

  1. Most companies have the following strategy: Operate in a large number of Disease Areas Focus on expanding product distribution Restrict their customer contact primarily to the doctor We propose a differentiated strategy Focus on key disease areas with high potential Engage with the patient directly while partnering with the doctor Going beyond product availability to providing an augmented product which includes services for disease management